Dublin, May 16, 2018 (GLOBE NEWSWIRE) -- The "Oral Proteins and Peptides Market (3rd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering.
The Oral Proteins and Peptides Market (3rd Edition), 2018-2030' report provides an extensive study on the current market landscape of orally administrable protein / peptide-based therapeutics, featuring a comprehensive discussion on the future potential of this evolving market. The field has captured the interest of several drug developers, including both small to mid-sized players and large companies. While more than half of these pipeline candidates are in the discovery / preclinical stages, around 28% of drug candidates are presently in advanced stages of evaluation (phase II and above).
The growing popularity of this upcoming class of therapeutics has led to the development of several oral protein / peptide-based product candidates for the treatment of a myriad of diseases. In addition, the need for efficient and patient-friendly treatment options for chronic disorders, such as diabetes, is estimated to boost the demand for oral proteins and peptides in the coming years. Despite their clinical and commercial success, oral formulations of protein / peptide-based drugs have been associated with multiple drawbacks, such as concerns related to unwanted enzymatic degradation, inherent structural complexities, high manufacturing costs and low bioavailability.
One of the key objectives of this study was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030.
In addition, we have provided the likely distribution of the market based on [A] therapeutic areas (autoimmune disorders, bone disorders, digestive and gastrointestinal disorders, hormonal disorders, infectious diseases, metabolic disorders, urogenital disorders and others), [B] molecule type (protein and peptide), [C] technology platforms, [D] key players, and [E] geography (North America (the US, Canada and Mexico), Europe (EU5 countries), Asia-Pacific and RoW). To account for the uncertainties associated with the growth of the oral proteins / peptides market and to add robustness to our model, we have provided three forecast scenarios, portraying conservative, base and optimistic tracks of the market's evolution. The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered both from secondary and primary sources. This enabled us to solicit inputs on upcoming opportunities and challenges that were considered to develop estimates for a more inclusive growth. The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain.
The report features detailed transcripts of interviews held with Dinesh Srinivasan (Director, Anthera Pharmaceuticals), Stig K Hansen (Co-founder and CEO, Carmot Therapeutics), Terry Dyck (CEO, IGY Life Sciences and Technology) and Richard Franklin (Director and CEO, Tarix Orphan). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified. Key Topics Covered:
1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Comparison of Biologics and Small Molecules 3.3. An Introduction to Proteins 3.3.1. Protein Structure 3.3.2. Classification 3.4. An Introduction to Peptides 3.4.1. Peptide Structure 3.4.2. Classification 3.4.2.1. Synthetic Peptides 3.4.2.2. Recombinant Peptides 3.5. Routes of Delivery for Proteins / Peptides 3.5.1. Parenteral Systemic Delivery 3.5.1.1. Intramuscular Route 3.5.1.2. Intravenous Route 3.5.1.3. Subcutaneous Route 3.5.2. Non-Parenteral Delivery 3.5.2.1. Buccal / Sublingual Route 3.5.2.2. Intranasal Route 3.5.2.3. Oral Route 3.5.2.4. Ocular Route 3.5.2.5. Pulmonary Route / Inhalation 3.5.2.6. Rectal Route 3.5.2.7. Transdermal Route 3.5.3. Comparison of Different Routes of Drug Delivery 3.6. Oral Delivery of Proteins / Peptides 3.6.1. Key Advantages of Oral Delivery 3.6.2. Key Challenges Associated with Oral Delivery 3.7. Approaches Used for Structural and Bioavailability Enhancement 3.7.1. Absorption Enhancers 3.7.2. Chemical Modification 3.7.3. Enzyme Inhibitors 3.7.4. Muco-Adhesive Polymeric Systems 3.7.5. Nanoparticular Delivery Systems 3.7.5.1. Liposomes 3.7.5.2. Nanoparticles / Microparticles 3.7.6. PEGylation 3.8. Concluding Remarks 4. MARKET OVERVIEW 4.1. Chapter Overview 4.2. Oral Proteins / Peptides: Development Pipeline 4.2.1. Distribution by Phase of Development 4.2.2. Distribution by Type of Molecule 4.2.3. Distribution by Therapeutic Areas 4.2.4. Distribution by Key Biological Targets 4.2.5. Distribution by Key Technology Platforms 4.2.6. Distribution by Leading Players 4.3. Oral Proteins / Peptides: Terminated / Discontinued Candidates 5. KEY INSIGHTS 5.1. Chapter Overview 5.2. Oral Proteins / Peptides Pipeline: Target Therapeutic Areas 5.3. Oral Proteins / Peptides Pipeline: Developer Landscape 5.4. Oral Proteins / Peptides Pipeline: Regional Landscape (Industry Players) 5.5. Oral Proteins / Peptides: Recent / Upcoming Conferences 6. KOL ANALYSIS 6.1. Chapter Overview 6.2. Current Research Landscape 6.3. Linzess and Trulance: Key Opinion Leaders 6.4. Most Prominent Key Opinion Leaders 7. KEY THERAPEUTIC AREAS 7.1. Chapter Overview 7.2. Metabolic Disorders 7.2.1. Diabetes 7.2.2. Obesity 7.2.3. Non-alcoholic Steatohepatitis (NASH) 7.3. Digestive and Gastrointestinal Disorders 7.3.1. Ulcerative Colitis 7.3.2. Crohn's Disease 7.4. Infectious Diseases 7.4.1. C. difficile Infections (CDIs) 7.5. Autoimmune Disorders 7.5.1. Celiac Disease 7.6. Hormonal Disorders 7.6.1. Acromegaly 7.7. Bone Disorders 7.7.1. Osteoporosis 8. MARKETED AND LATE-STAGE DRUG PROFILES 8.1. Chapter Overview 8.2. Linzess / Constella / Linaclotide (Ironwood Pharmaceuticals) 8.3. Trulance / Plecanatide (Synergy Pharmaceuticals) 8.4. TBRIA / OSTORA / Oral Calcitonin (Tarsa Therapeutics / Enteris BioPharma) 8.5. ALLN-177 (Allena Pharmaceuticals) 8.6. Mycapssa / Octreolin / Oral Octreotide (Chiasma Pharma) 8.7. NTRA-2112 (Nutrinia) 8.8. Oral Semaglutide / NN9924 / OG217SC (Novo Nordisk / Emisphere Technologies) 9. CASE STUDIES: MINIRIN, SANDIMMUNE AND SOLLPURA 9.1. Chapter Overview 9.2. Minirin / DDAVP (Ferring Pharmaceuticals) 9.3. Sandimmune / Neoral (Novartis) 9.4. Sollpura / Liprotamase (Anthera Pharmaceuticals) 10. ORAL DRUG DELIVERY TECHNOLOGY PLATFORMS 10.1. Chapter Overview 10.2. Oral Drug Delivery: List of Technology Platforms 10.3. Technology Profiles 10.3.1. Axcess Oral Drug Delivery Technology (Proxima Concepts) 10.3.2. Eligen Technology (Emisphere Technologies) 10.3.3. Entera Technology (Entera Bio) 10.3.4. NTRA Oral Delivery Technology (Nutrinia) 10.3.5. Peptelligence Technology (Enteris BioPharma) 10.3.6. Protein Oral Delivery (POD) Technology (Oramed Pharmaceuticals) 10.3.7. Transient Permeability Enhancer (TPE) Technology (Chiasma Pharma) 10.3.8. Uroguanylin Analogue Technology (Synergy Pharmaceuticals) 11. PRODUCT COMPETITIVENESS ANALYSIS 11.1. Chapter Overview 11.2. Scope and Methodology 11.3. Product Competitiveness Analysis: Key Technologies 12. FUNDING AND INVESTMENT ANALYSIS 12.1. Chapter Overview 12.2. Types of Funding 12.3. Oral Proteins / Peptides: Funding and Investment Analysis 12.3.1. Analysis by Cumulative Number of Funding Instances 12.3.2. Analysis by Cumulative Amount Invested 12.3.3. Analysis by Type of Funding 12.3.4. Analysis by Most Active Players 12.3.5. Analysis by Most Active Investors 12.4. Concluding Remarks 13. RECENT COLLABORATIONS 13.1. Chapter Overview 13.2. Partnership Models 13.3. Oral Proteins / Peptides: List of Partnerships 13.4. Partnership Analysis 14. PUBLICATION ANALYSIS 14.1. Chapter Overview 14.2. Oral Proteins / Peptides: List of Publications, 2017 14.2.1. Quarter-Wise Trend (Q1-Q4 2017) 14.2.2. Analysis by Type of Study 14.2.3. Analysis by Key Biological Targets 14.2.4. Analysis by Key Journals 15. EMERGING TRENDS ON SOCIAL MEDIA 15.1. Chapter Overview 15.2. Oral Proteins / Peptides: Trends on Twitter 15.3. Year-Wise Activity Analysis (2013-2017) 15.4. Popular Keywords 15.5. Popular Therapeutic Areas 15.6. Popular Biological Targets 15.7. Popular Technology Platforms 15.8. Popular Drugs 15.9. Popular Players 16. MARKET FORECAST AND OPPORTUNITY ANALYSIS 16.1. Chapter Overview 16.2. Scope and Limitations 16.3. Forecast Methodology 16.4. Overall Oral Proteins / Peptides Market, 2018-2030 16.5. Oral Proteins / Peptides Market: Product-Wise Sales Forecasts 16.5.1. Linzess / Constella / Linaclotide (Ironwood Pharmaceuticals) 16.5.2. Trulance / Plecanatide (Synergy Pharmaceuticals) 16.5.3. TBRIA / OSTORA / Oral Calcitonin (Tarsa Therapeutics / Enteris BioPharma) 16.5.4. ALLN-177 (Allena Pharmaceuticals) 16.5.5. Mycapssa / Octreolin (Chiasma Pharma) 16.5.6. NTRA-2112 (Nutrinia) 16.5.7. Oral Semaglutide / NN9924 / OG217SC (Novo Nordisk / Emisphere Technologies) 16.5.8. Larazotide INN-202 (Innovate Biopharmaceuticals) 16.5.9. NTRA-9620 (Nutrinia) 16.5.10. AG013 (Oragenics / Intrexon) 16.5.11. IMM-124E (Immuron) 16.5.12. OPRX-106 (Protalix Biotherapeutics) 16.5.13. KORSUVATM / Oral CR845 / Difelikefalin (Enteris BioPharma / Cara Therapeutics) 16.5.14. Oral HDV Insulin (Diasome Pharmaceuticals) 16.5.15. ORMD-0801 (Oramed Pharmaceuticals) 16.5.16. Oshadi Icp Oral Insulin (Oshadi Drug Administration) 16.5.17. Ovarest / Oral Leuprolide Tablet (Enteris BioPharma) 16.5.18. SYN-004 / Ribaxamase (Synthetic Biologics) 16.5.19. V565 (VHsquared) 17. CASE STUDY: PROTEIN / PEPTIDE MANUFACTURING 17.1. Chapter Overview 17.2. Key Steps Involved in Protein / Peptide Manufacturing 17.3. Challenges Associated with Protein / Peptide Manufacturing 17.4. Current Scenario of Protein / Peptide Manufacturing 17.5. Growing Demand for Contract Manufacturing 17.5.1. Selecting A Suitable CMO Partner 17.5.2. List of Protein / Peptide CMOs 18. SWOT ANALYSIS 18.1. Chapter Overview 18.2. Comparison of SWOT Factors 19. CONCLUSION 19.1. Advances in Oral Drug Delivery have Enabled the Development of Protein / Peptide Therapeutics Offering Improved Patient Compliance 19.2. The Field is Characterized by a Promising Development Pipeline, Featuring Molecules Against a Diverse Range of Biological Targets 19.3. Oral Protein / Peptide-based Therapeutics are being Designed to Treat a Wide Spectrum of Disease Indications; however, the Primary Focus is on Metabolic and Gastrointestinal Disorders 19.4. In Addition to Established Players, a Number of Start-ups, Backed by Venture Capital Investors, are Making Significant Contributions in this Domain 19.5. Several Stakeholders have Entered into Strategic Alliances Aimed at Promoting Research and Advancing Product Development Efforts 19.6. Post the Approval of Multiple Late-Phase Product Candidates, the Market is Anticipated to Grow Significantly in the Foreseen Future 19.7. Concluding Remarks 20. EXECUTIVE INSIGHTS 20.1. Chapter Overview 20.2. Anthera Pharmaceuticals 20.2.1. Company Snapshot 20.2.2. Interview Transcript: Dinesh Srinivasan, Director 20.3. Carmot Therapeutics 20.3.1. Company Snapshot 20.3.2. Interview Transcript: Stig K Hansen, CEO 20.4. IGY Life Sciences and Technology 20.4.1. Company Snapshot 20.4.2. Interview Transcript: Terry Dyck, President and CEO 20.5. Tarix Orphan 20.5.1. Company Snapshot 20.5.2. Interview Transcript: Richard Franklin, Director and CEO 21. APPENDIX 1: TABULATED DATA 22. APPENDIX 2: LIST OF COMPANIES
Companies Mentioned
- 3P Biopharmaceuticals
- 7-Med Health Ventures
- Aalto Scientific
- Abbott Laboratories
- AbbVie
- Abeona Therapeutics
- Abingworth
- ABL Venture Capital
- Abzena
- Access Pharmaceuticals
- ACES Pharma
- Acorn Biomedical
- ActoGeniX
- Adage Capital Management
- Adams, Harkness & Hill Technology Ventures
- Adar Biotech
- Adcock Ingram
- Aegis Capital
- Aescap Venture
- Affilogic
- Affinity Life Sciences
- AIMM Therapeutics
- Ajinomoto Althea
- Alaven Pharmaceutical
- Alba Therapeutics
- Albireo Pharma
- Alcami
- Alchemia
- Aldevron
- Allena Pharmaceuticals
- Allergan
- Alliance Medical Products
- Almac
- Almirall
- Alnara Pharmaceuticals
- Alta Biopharma Partners
- Althea Technologies
- Altus Pharmaceuticals
- Alza Pharmaceuticals
- Amarillo Biosciences
- AmatsiQBiologicals
- AmbioPharm
- Amgen
- Anaheim Clinical Trials
- Anthera Pharmaceuticals
- Aphios
- Apotex
- Aptalis Pharma
- Aquestive Therapeutics
- Aravis Ventures
- ARCH Venture Partners
- Arena Pharmaceuticals
- ArisGen
- Arisaph Pharmaceuticals
- Armenian Development Agency
- Asahi Glass
- Ascent Biomedical Ventures
- Assaf Harofeh Medical Center
- Assembly Biosciences
- Astellas Pharma
- AstraZeneca
- Asymchem Laboratories
- Atara Technology Ventures
- Atrix Laboratories
- Augusta University
- AURA Biotechnologies
- AutekBio
- Avaxia Biologics
- Avid Bioservices
- Axcan Pharma
- AzurRx BioPharma
- Bachem
- Baekeland Funds
- Biomedical Advanced Research and Development Authority
- Barr Pharmaceuticals
- Batavia Biosciences
- Baxter BioPharma Solutions
- Bayer
- BCN Peptides
- Beacon Angels
- Beijing Friendship Hospital
- Beijing Tiantan Hospital
- Beijing Tongren Hospital
- Bessemer Venture Partners
- Beta Fund
- Bharat Serums and Vaccines
- BIBITEC
- Bill & Melinda Gates Foundation
- BIND Therapeutics
- BINEX
- Bio Elpida
- Biocell
- Biocon
- BioConnection
- Biodel
- Bio Farma
- Biogen
- Bio-Kinetic Clinical Applications
- Biolaxy
- Biolingus
- Biological Process Development Facility, University of Nebraska
- Biomatik
- Biomay
- BioPharmaceuticals Australia
- Biosynergy
- Bio-Synthesis
- Biotech Fund Flanders
- BioTechLogic
- Biotechnology and Biological Sciences Research Council
- Biotechpharma
- BioVectra
- BioVeda Capital
- Biovest
- Biovian
- Black Beret Life Sciences
- Boehringer Ingelheim Boehringer
- Bone Medical
- Bossa Nova Investmentos
- Boston Harbor Angels
- Botanix Pharmaceuticals
- Broadview Ventures
- Bumi Medic
- Buttonwood Financial
- BZ Bank
- Cadila Healthcare
- Calvert Research Institute
- Canaan Partners
- Canada Armenia Trading House
- Capsugel
- Cara Therapeutics
- CARBOGEN AMCIS
- Cardinal Health
- Carmot Therapeutics
- Catalent Pharma
- Cathay Venture
- Cedars-Sinai Medical Center
- Cell Culture Company
- Celltrion
- Celonic
- Center for Biocatalysis and Bioprocessing, University of Iowa
- Century Pharmaceuticals
- Cerbios-Pharma
- Changhai Hospital
- Changzheng Hospital
- Charles River Laboratories
- Chattem
- Chemi Peptides
- ChemPartner
- Cherrystone Angels
- Chiasma Pharma
- Chinese PLA General Hospital
- Chong Kun Dang Pharmaceutical
- Circle33
- ClinSearch
- CNF Investments
- Cobra Biologics
- Column Group
- Commercial & External Partnership, Industrial Affairs (CEPiA)
- Connecticut Innovations
- Constant Pharmaceuticals
- Cook Pharmica
- CordenPharma
- CoreMed
- Cosmo Pharmaceuticals
- Courtagen Life Sciences
- CPC Scientific Peptide Company
- CRG
- Crystal Horizon Investments
- CureDM
- Cystic Fibrosis Foundation Therapeutics
- CytoPharm
- Cytovance Biologics
- D.N.A Biomedical Solutions
- Dalton Pharma Services
- Devon Park BioVentures
- Diabetology
- Diasome Pharmaceuticals
- Digestive Care
- DM Bio
- Docor International
- Duke University
- Edward P. Bass Group
- EirGenix
- Eli Lilly
- Elite Research Institute
- European Medical Association
- Embio
- Emergent BioSolutions
- Emisphere Technologies
- Emory University
- Encap Drug Delivery
- Encorium Group
- enGene
- Engineered BioPharmaceuticals
- Engineering and Physical Sciences Research Council
- Entera Bio
- Enteris BioPharma
- Enterome Bioscience
- Entrega
- Esperante Ventures
- Eti Karle Clinical
- EuBiologics
- EUCODIS Bioscience
- Eurogentec
- European Commission
- European Cystic Fibrosis Society
- Evonik Industries
- F2 Capital
- F3 Ventures
- Ferrer Internacional
- Ferring Pharmaceuticals
- Fidelity Management & Research Company
- Firebird Global Master Fund
- First Affiliated Hospital of Harbin Medical University
- Forbion Capital Partners
- Foresite Capital
- Forest Laboratories
- Frazier Healthcare Partners
- FUJIFILM Diosynth Biotechnologies
- Gala Biotech
- GD Searle
- GE Healthcare
- General Hospital of Shenyang Military Region
- Generex Biotechnology
- GenIBET Biopharmaceuticals
- Genta
- GF Ventures
- GGV Capital
- Gila Therapeutics
- Gimv
- GlaxoSmithKline
- Glycotope Biotechnology
- Golden Seeds
- Goodwin Biotechnology
- Google Ventures
- GP-Pharm
- Grand River Aseptic Manufacturing
- Granite State Angels
- Great Point Partners
- GTP Technology
- H.I.G. BioHealth Partners
- Hadassah Medical Center
- HALIX
- Harvard Business School Angels
- Hayashibara Biochemical Laboratories
- HBM BioCapital
- HBM Partners
- Health Biotech
- Hefei Tianhui Incubator of Technologies
- Hemispherx Biopharma
- Hepasome Pharmaceuticals
- Heptares Therapeutics
- Hetero Drugs
- Hoechst Marion Roussel
- Hoffman La Roche
- Hong Kong Institute of Biotechnology
- Horizons Ventures
- Hovione
- iBio
- IDT Biologika
- IGY Life Sciences and Technology
- Immuron
- InCube Ventures
- Ingro Finanz
- Inno Biologics
- InnoMed Fund
- Innovate Biopharmaceuticals
- Institute for Promotion of Innovation by Science and Technology
- Intas Pharmaceuticals
- Integrity Bio
- Intrexon
- Ippon Capital
- Ipsen Pharma
- Ironwood Pharmaceuticals
- iSelect Fund
- Ivax Pharmaceuticals
- Janssen Biotech
- Jennison Associates
- JMP Securities Stifel
- Johnson & Johnson
- Jordanian Pharmaceutical Manufacturing
- Joslin Diabetes Center
- Julphar Gulf Pharmaceutical Industries
- Juvenile Diabetes Research Foundation (JDRF)
- Kamat PharmaTech
- KBI Biopharma
- Kemwell Biopharma
- KeyBioscience
- KPC Pharmaceuticals
- LAMPIRE Biological Laboratories
- LaunchPad Venture Group
- Layered Service Provider (LSP)
- LFB BIOMANUFACTURING
- Life Sciences Partners
- Lilly Ventures
- LODH Immunology Fund
- Longevity Biotech
- Lonza
- LuinaBio
- Lumira Capital
- Lundbeckfonden Ventures
- Lyfebulb
- Maine Angels
- Mallinckrodt Pharmaceuticals
- Marathon Capital Development Fund
- Maruishi Pharmaceutical Company
- Mass Medical Angels
- Massachusetts Institute of Technology
- Maverick Capital
- Maxim Group
- Mayo Clinic Foundation
- McDonald Partners
- Medeva Pharmaceuticals
- Medicxi Ventures
- MedImmune
- Medpace
- Menarini Biotech
- Mentor Pharmaceuticals
- Merck
- Meridian Life Science
- Merrion Pharmaceuticals
- Merro Pharmaceutical
- MHR Fund Management
- MicroBiopharm Japan
- MidaSol Therapeutics
- Midatech Pharma
- Millennium Pharmaceuticals
- Ministry of Industry, Trade and Labor of Israel
- Mitsubishi International
- Mitsubishi Tanabe Pharma
- Molecular and Cellular Therapeutics, University of Minnesota
- Monash University
- Montaur Capital Partners
- Morgan Stanley Investment Management
- MPM Capital
- MSD Partners
- MVM Life Science Partners
- Mylan
- NanoMega Medical
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke
- National Multiple Sclerosis Society
- Neuland Laboratories
- New Generation Technology
- New River Management
- NewVa Capital Partners
- Niagara University
- Nitto Avecia Pharma Services
- Nobex
- NOD Pharmaceuticals
- Nordmark Arzneimittel
- Nordic Biosciences
- North Country Angels
- Northwest Pituitary Center, Oregon Health & Science University
- Nova Laboratories
- Novartis
- Novartis Venture Fund
- Novasep
- Novetide
- Novex
- Novimmune
- Novo Nordisk
- Nutrinia
- OctoPlus
- Ofer Hi-Tech Group
- Oklahoma Foundation for Digestive Research
- Olon
- Omnia Biologics
- Oragenics
- Oramed Pharmaceuticals
- Orange County Research Center
- OrbiMed
- Orexigen Therapeutics
- Oshadi Drug Administration
- OsoBio
- Oxford Finance
- P&G Pharmaceuticals
- Pacific Venture Opportunity Fund
- Panacea Biotec
- Paperboy Ventures
- Paragon Bioservices
- Partner Fund Management
- Patheon
- Peking University First Hospital
- Peking University Peoples Hospital
- Pendopharm
- Perceptive Advisors
- Pfizer
- Pfizer CentreOne
- Pharmacia & Upjohn
- Pharmstandard International
- Pictet Private Equity Investors
- Pinemount Investments
- Ping An Ventures
- Piramal Pharma Solutions
- Pituitary Center, Baylor St. Luke's Medical Center
- PlasmaTech Biopharmaceuticals
- PLIVA
- Polymun Scientific
- PolyPeptide Group
- Pontifax
- Praxis Pharmaceutical
- PREMAS Biotech
- ProBioGen
- Productos Biologicos
- ProJect Pharmaceutics
- ProMab Biotechnologies
- Prometheus Laboratories
- Protagonist Therapeutics
- Protalix Biotherapeutics
- Provantage Biodevelopment Services (Merck Millipore)
- PureTech Health
- PvP Biologics
- PX'Therapeutics
- PYRAMID Laboratories
- QIC BioVentures
- Qilu Hospital of Shandong University
- QS Pharma
- Quaker BioVentures
- Queen's University
- RA Capital Management
- Rambam Health Care Campus
- Rani Therapeutics
- Rebel Pharmaceuticals
- Reliance Life Sciences
- Rentschler Biopharma
- Rho Ventures
- Richter-Helm BioLogics
- Ridgeback Capital
- Rock Springs Capital
- Rosetta Capital
- Ruijin Hospital
- Saffelberg Investments
- Sahlgrenska University Hospital
- Salix Pharmaceuticals
- Sandoz Pharmaceuticals
- Sanofi
- Sanyal Biotechnology
- Schering-Plough
- Scientific Health Development Partners
- Scientific Protein Laboratories
- SciGen
- Seachaid Pharmaceuticals
- Senn Chemicals
- Shanghai Zhongshan Hospital
- Sheba Hospital
- Shionogi
- Shire
- Sichuang Provincial People's Hospital
- Sigma Capital Management
- Sigmoid Pharma
- Slater Technology Fund
- Sofinnova Ventures
- Square 1 Bank
- SR One
- SRZ Properties
- Stallergenes
- Starfish Ventures
- Stealth BioTherapeutics
- Stevanato Group
- Sucampo Pharmaceuticals
- SV Health Investors
- Swiss Caps
- Symbiosis Pharmaceutical Services
- SynCo Bio Partners
- Synergy Pharmaceuticals
- Synermore Biologics
- Syngene
- Synthetic Biologics
- Syntex Pharm
- Takeda Pharmaceutical
- Takeda Ventures
- Tamares Capital
- Tamarix Technologies Group
- Tapemark
- Tarix Pharmaceuticals
- Tarsa Therapeutics
- Tech Coast Angels
- Temasek Holdings
- Teva Pharmaceutical
- Texas Tech University Health Sciences Center
- The Column Group
- The First Affiliated Hospital, Zhongshan University
- The Halifax Group
- The Native Antigen Company
- Thiel Foundation
- Third Affiliated Hospital of Guangzhou Medical University
- Therapure Biopharma
- Thermo Fisher Scientific
- Third Rock Ventures
- Third Security
- Tiziana Life Sciences
- TNT Pharma
- TPG Biotech
- TPG Growth
- Transgene Biotek
- TranXenoGen
- Trenzyme
- TriHealth
- TVM Capital
- UCB Pharma
- Unigene Laboratories
- Union Hospital of Tongji Medical College of Huazhong University of Science & Technology
- United States Food and Drug Administration
- University of Washington
- University Hospital of South Manchester
- University of Alabama Fermentation Facility
- University of Alberta
- University of California
- University of Montreal
- University of Nebraska
- University of Southern California
- University of Texas
- University of Virginia
- University of Washington
- USV
- Vanderbilt-Ingram Cancer Center
- Varuma
- Venrock
- Ventria Bioscience
- VentureHealth
- Vertex Pharmaceuticals
- Vetter Pharma
- VHsquared
- Victory Park Capital
- Virginia Commonwealth University
- Virtus Inspire Ventures
- Vista Biologicals
- VIVUS
- vTv Therapeutics
- WACKER Biotech
- Waisman Biomanufacturing
- Watson Laboratories
- Wellington Management Company
- West China Hospital
- White Oak Global Advisors
- Wingate Institute of Neurogastroenterology
- WuXi AppTec
- WuXi Healthcare Ventures
- Wyeth Pharmaceuticals
- XBiotech
- Yissum
- Zealand Pharma
- Zosano Pharma
- Zhongshan Hospital
- Ziff Asset Management
For more information about this report visit https://www.researchandmarkets.com/research/9...s_and?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Drug Delivery
